TNYA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TNYA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tenaya Therapeutics's Enterprise Value is $237.56 Mil. Tenaya Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-131.19 Mil. Therefore, Tenaya Therapeutics's EV-to-EBIT for today is -1.81.
The historical rank and industry rank for Tenaya Therapeutics's EV-to-EBIT or its related term are showing as below:
During the past 5 years, the highest EV-to-EBIT of Tenaya Therapeutics was 346.57. The lowest was -4155.71. And the median was 0.00.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Tenaya Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $129.17 Mil. Tenaya Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-131.19 Mil. Tenaya Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -101.56%.
The historical data trend for Tenaya Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenaya Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-EBIT | - | - | -7.51 | 0.29 | -0.98 |
Tenaya Therapeutics Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBIT | Get a 7-Day Free Trial | 0.29 | -0.44 | -2.07 | -0.48 | -0.98 |
For the Biotechnology subindustry, Tenaya Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Tenaya Therapeutics's EV-to-EBIT falls into.
Tenaya Therapeutics's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 237.556 | / | -131.193 | |
= | -1.81 |
Tenaya Therapeutics's current Enterprise Value is $237.56 Mil.
Tenaya Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-131.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenaya Therapeutics (NAS:TNYA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Tenaya Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2023 ) |
= | -131.193 | / | 129.172172 | |
= | -101.56 % |
Tenaya Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $129.17 Mil.
Tenaya Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-131.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Tenaya Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy Hoey | officer: Chief Scientific Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080 |
Leone D Patterson | officer: Chief Fin and Bus. Officer | |
Whittemore Tingley | officer: Chief Medical Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Faraz Ali | director, officer: Chief Executive Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080 |
David V Goeddel | director, 10 percent owner | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Iii Gp, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Amy L. Burroughs | director | TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Column Group Iii, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Opportunity Iii Gp, Lp | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Tcg Opportunity Iii Gp, Llc | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Column Group Opportunity Iii, Lp | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Deepak Srivastava | director | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Column Group Iii-a, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Eli Casdin | director | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Casdin Capital, Llc | director | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
From GuruFocus
By sperokesalga sperokesalga • 05-10-2023
By GlobeNewswire GlobeNewswire • 11-21-2022
By Marketwired • 08-31-2023
By Stock market mentor Stock market mentor • 02-07-2023
By Value_Insider Value_Insider • 11-10-2022
By Marketwired • 10-02-2023
By Value_Insider Value_Insider • 11-23-2022
By Marketwired • 08-09-2023
By Value_Insider Value_Insider • 11-16-2022
By Stock market mentor Stock market mentor • 01-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.